Xin Wei1, Ke Chen1, Dong-Chang Li1, He Li2, Liang Zhu3, Zheng-Guang Wang1. 1. The General Surgery Department, The First Affiliated Hospital of Anhui Medical University, Hefei, China. 2. The Emergency Surgery, The Second Affiliated Hospital of Anhui Medical University, Hefei, China. 3. The General Surgery Department, Anhui Provincial Hospital, Hefei, China.
Abstract
Background: Small bowel adenocarcinoma (SBA) is a rare malignancy that accounts for 3% of all gastrointestinal tumors. We evaluated the clinical characteristics, outcomes, and prognostic factors of primary SBAs. Methods: We retrospectively analyzed the clinicopathological features and clinical outcomes of 300 patients with SBA from three institutions in China between January 2003 and July 2020. Overall survival (OS) was analyzed using the Kaplan-Meier method and it was statistically compared using the log-rank test. Single-variable and multivariate analyses were used to identify the significant correlates of OS. Results: The primary tumor was on the duodenal papilla in 156 patients (52%), in the duodenum in 60 patients (20%), and in the jejunum-ileum in 84 patients (28%). The median OS of the entire cohort was 32.5 months (range, 0-213 months), with a 1-year OS rate of 78.0%. For jejunoileal adenocarcinoma, advanced age, advanced T stage, advanced N stage, more positive lymph nodes, distant metastasis, high carcinoembryonic antigen (CEA), and lymphocyte-to-monocyte ratio < 2.32 predicted worse survival on single-variable analysis. Multivariate analysis showed that advanced age, advanced tumor node metastases (TNM) stage, high CEA level, high alpha fetoprotein (AFP) level, and low prealbumin level were independent prognostic factors for non-ampullary SBA. The independent prognostic factors for duodenal papilla adenocarcinoma included TNM Stage III, nerve invasion, low platelet/lymphocyte ratio, and high CA19-9. Conclusion: We found different independent prognostic factors for tumors at different locations. This finding warrants further investigation to ensure more effective management strategies for SBA.
Background: Small bowel adenocarcinoma (SBA) is a rare malignancy that accounts for 3% of all gastrointestinal tumors. We evaluated the clinical characteristics, outcomes, and prognostic factors of primary SBAs. Methods: We retrospectively analyzed the clinicopathological features and clinical outcomes of 300 patients with SBA from three institutions in China between January 2003 and July 2020. Overall survival (OS) was analyzed using the Kaplan-Meier method and it was statistically compared using the log-rank test. Single-variable and multivariate analyses were used to identify the significant correlates of OS. Results: The primary tumor was on the duodenal papilla in 156 patients (52%), in the duodenum in 60 patients (20%), and in the jejunum-ileum in 84 patients (28%). The median OS of the entire cohort was 32.5 months (range, 0-213 months), with a 1-year OS rate of 78.0%. For jejunoileal adenocarcinoma, advanced age, advanced T stage, advanced N stage, more positive lymph nodes, distant metastasis, high carcinoembryonic antigen (CEA), and lymphocyte-to-monocyte ratio < 2.32 predicted worse survival on single-variable analysis. Multivariate analysis showed that advanced age, advanced tumor node metastases (TNM) stage, high CEA level, high alpha fetoprotein (AFP) level, and low prealbumin level were independent prognostic factors for non-ampullary SBA. The independent prognostic factors for duodenal papilla adenocarcinoma included TNM Stage III, nerve invasion, low platelet/lymphocyte ratio, and high CA19-9. Conclusion: We found different independent prognostic factors for tumors at different locations. This finding warrants further investigation to ensure more effective management strategies for SBA.
Authors: Brandon M Huffman; Zhaohui Jin; Siddhartha Yadav; Shruti Patel; David M Nagorney; Mark J Truty; Robert R McWilliams; Thorvardur R Halfdanarson; Amit Mahipal Journal: Clin Colorectal Cancer Date: 2019-05-15 Impact factor: 4.481
Authors: Al B Benson; Alan P Venook; Mahmoud M Al-Hawary; Mustafa A Arain; Yi-Jen Chen; Kristen K Ciombor; Stacey A Cohen; Harry S Cooper; Dustin A Deming; Ignacio Garrido-Laguna; Jean L Grem; Sarah E Hoffe; Joleen Hubbard; Steven Hunt; Ahmed Kamel; Natalie Kirilcuk; Smitha Krishnamurthi; Wells A Messersmith; Jeffrey Meyerhardt; Eric D Miller; Mary F Mulcahy; Steven Nurkin; Michael J Overman; Aparna Parikh; Hitendra Patel; Katrina S Pedersen; Leonard B Saltz; Charles Schneider; David Shibata; John M Skibber; Constantinos T Sofocleous; Elena M Stoffel; Eden Stotsky-Himelfarb; Christopher G Willett; Alyse Johnson-Chilla; Kristina M Gregory; Lisa A Gurski Journal: J Natl Compr Canc Netw Date: 2019-09-01 Impact factor: 11.908
Authors: Emanuela Dell'Aquila; Tea Zeppola; Marco Stellato; Francesco Pantano; Mario Scartozzi; Cristina Madaudo; Filippo Pietrantonio; Chiara Cremolini; Giuseppe Aprile; Bruno Vincenzi; Roberto Moretto; Marco Puzzoni; Silvio Ken Garattini; Riccardo Lobefaro; Giuseppe Tonini; Daniele Santini Journal: Clin Med Insights Oncol Date: 2020-08-04
Authors: Karl Y Bilimoria; David J Bentrem; Jeffrey D Wayne; Clifford Y Ko; Charles L Bennett; Mark S Talamonti Journal: Ann Surg Date: 2009-01 Impact factor: 12.969
Authors: Laura L Meijer; Marin Strijker; Jacob K de Bakker; Jurgen Gj Toennaer; Barbara M Zonderhuis; Hans J van der Vliet; Hanneke Wilmink; Joanne Verheij; Freek Daams; Olivier R Busch; Nicole Ct van Grieken; Marc G Besselink; Geert Kazemier Journal: World J Gastrointest Oncol Date: 2020-03-15